MAZE
Live / Allowed — Notice of allowance issued (as of 27 Jan 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 21 Oct 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98811175
- Mark type
- Stylized text
- Filed
- 21 Oct 2024
- Published for opposition
- 02 Dec 2025
- Attorney of record
- Joyce Liou
Goods and services
- Class 001 — Chemicals: Diagnostic preparations for scientific or research use other than for medical use; assays and reagents for scientific or medical research use; genetic testing preparations for scientific or medical research use, namely, assays and reagents for use in genetic and biomedical research; cells for scientific or medical research use
- Class 005 — Pharmaceuticals: Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical products; pharmaceutical preparations for treating genetic diseases and disorders; pharmaceutical preparations for treating lysosomal storage disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculoskeletal system, and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart diseases and disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases and disorders; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in urology; pharmaceutical preparations for the prevention and treatment of obesity; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical products for the prevention and treatment of bone diseases; pharmaceutical products for the prevention and treatment of respiratory diseases and asthma; reagents for medical use; genetic testing preparations for medical purposes, namely, medical diagnostic reagents and assays for testing of body fluids; cells for medical or clinical use; medical diagnostic and testing assays, namely, medical diagnostic reagents and assays for testing of body fluids
- Class 042 — Scientific and technological services: Pharmaceutical research and development services; research in the field of genetic modifiers and related therapeutics for genetic diseases; research in the field of genetic variations linked to medical diseases or conditions; research in the field of variant functionalization
Owner
- Maze Therapeutics, Inc., South San Francisco, CA, US
- Maze Therapeutics, Inc., South San Francisco, CA, US
Prosecution history
- 27 Jan 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 02 Dec 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 02 Dec 2025 — PUBLISHED FOR OPPOSITION
- 26 Nov 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 03 Nov 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 30 Oct 2025 — EXAMINER'S AMENDMENT ENTERED
- 30 Oct 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 30 Oct 2025 — EXAMINERS AMENDMENT E-MAILED
- 30 Oct 2025 — EXAMINERS AMENDMENT -WRITTEN
- 23 Oct 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 23 Oct 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 23 Oct 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 01 Jul 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 01 Jul 2025 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 20 May 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED